BACKGROUND: Blockade of the CD28 costimulatory molecule by recombinant human cytotoxic T lymphocyte (CTL)-associated antigen (CTLA4)-Ig or CD40-CD154 interaction with the monoclonal antibody 5C8 together with donor-specific transfusion led to enhanced engraftment in the canine model of dog leukocyte antigen (DLA)-identical marrow transplantation after 1 Gy total body irradiation. To reduce or eliminate total body irradiation conditioning regimens, we have sought to develop canine specific reagents. METHODS: We have created a fusion protein of the extracellular domain of canine (c) CTLA-4 linked to the hinge-CH2-CH3 domains of canine IgG1 in a pcDNA3.1+ vector. Chinese hamster ovarian cells were cotransfected with CTLA4-Ig vector and a dihydrofolate reductase-containing vector. Stable, high producing clones were generated. RESULTS: Cell binding and mixed leukocyte reactions indicated no significant differences in activity between cCTLA4-Ig and human CTLA4-Ig. Mixed leukocyte reaction data indicated that combinations of cCTLA4-Ig and the monoclonal antibody 5C8 were superior in blocking H-thymidine uptake compared to either reagent alone. In dogs, the circulating half-life of cCTLA4-Ig was approximately 7 days with no immune response against the fusion protein. Finally, two injections of cCTLA4-Ig effectively tolerized two dogs against eight consecutive challenges with sheep red blood cells, given over 330 days as indicated by a complete block of IgG antibody production. Tolerance was broken in one of the two dogs when a ninth injection of sheep red blood cell was given subcutaneously in incomplete Freund's adjuvant. CONCLUSION: cCTLA4-Ig is an effective nonimmunogenic blocking reagent of the CD28 costimulatory pathway in dogs and is a promising reagent for studies of tolerance induction in hematopoietic cell transplantation in the canine model.
BACKGROUND: Blockade of the CD28 costimulatory molecule by recombinant humancytotoxic T lymphocyte (CTL)-associated antigen (CTLA4)-Ig or CD40-CD154 interaction with the monoclonal antibody 5C8 together with donor-specific transfusion led to enhanced engraftment in the canine model of dog leukocyte antigen (DLA)-identical marrow transplantation after 1 Gy total body irradiation. To reduce or eliminate total body irradiation conditioning regimens, we have sought to develop canine specific reagents. METHODS: We have created a fusion protein of the extracellular domain of canine (c) CTLA-4 linked to the hinge-CH2-CH3 domains of canine IgG1 in a pcDNA3.1+ vector. Chinese hamster ovarian cells were cotransfected with CTLA4-Ig vector and a dihydrofolate reductase-containing vector. Stable, high producing clones were generated. RESULTS: Cell binding and mixed leukocyte reactions indicated no significant differences in activity between cCTLA4-Ig and humanCTLA4-Ig. Mixed leukocyte reaction data indicated that combinations of cCTLA4-Ig and the monoclonal antibody 5C8 were superior in blocking H-thymidine uptake compared to either reagent alone. In dogs, the circulating half-life of cCTLA4-Ig was approximately 7 days with no immune response against the fusion protein. Finally, two injections of cCTLA4-Ig effectively tolerized two dogs against eight consecutive challenges with sheep red blood cells, given over 330 days as indicated by a complete block of IgG antibody production. Tolerance was broken in one of the two dogs when a ninth injection of sheep red blood cell was given subcutaneously in incomplete Freund's adjuvant. CONCLUSION:cCTLA4-Ig is an effective nonimmunogenic blocking reagent of the CD28 costimulatory pathway in dogs and is a promising reagent for studies of tolerance induction in hematopoietic cell transplantation in the canine model.
Authors: A D Wells; X C Li; Y Li; M C Walsh; X X Zheng; Z Wu; G Nuñez; A Tang; M Sayegh; W W Hancock; T B Strom; L A Turka Journal: Nat Med Date: 1999-11 Impact factor: 53.440
Authors: R Storb; C Yu; J M Zaucha; H J Deeg; G Georges; H P Kiem; R A Nash; P A McSweeney; J L Wagner Journal: Blood Date: 1999-10-01 Impact factor: 22.113
Authors: George E Georges; Marina Lesnikova; Rainer Storb; Murad Yunusov; Marie-Térèse Little; Richard A Nash Journal: Biol Blood Marrow Transplant Date: 2003-04 Impact factor: 5.742
Authors: Scott S Graves; Diane M Stone; Carol Loretz; Laura J Peterson; Marina Lesnikova; Billanna Hwang; George E Georges; Richard Nash; Rainer Storb Journal: Transplantation Date: 2011-04-27 Impact factor: 4.939
Authors: Jennifer L Gori; Brian C Beard; Nathaniel P Williams; Christina Ironside; Debra Swanson; R Scott McIvor; Hans-Peter Kiem Journal: J Gene Med Date: 2013 Jun-Jul Impact factor: 4.565
Authors: Benjamin Watkins; Muna Qayed; Courtney McCracken; Brandi Bratrude; Kayla Betz; Yvonne Suessmuth; Alison Yu; Shauna Sinclair; Scott Furlan; Steven Bosinger; Victor Tkachev; James Rhodes; Audrey Grizzle Tumlin; Alexandria Narayan; Kayla Cribbin; Scott Gillespie; Ted A Gooley; Marcelo C Pasquini; Kyle Hebert; Urvi Kapoor; Andre Rogatko; Mourad Tighiouart; Sungjin Kim; Catherine Bresee; Sung W Choi; Jeffrey Davis; Christine Duncan; Roger Giller; Michael Grimley; Andrew C Harris; David Jacobsohn; Nahal Lalefar; Maxim Norkin; Nosha Farhadfar; Michael A Pulsipher; Shalini Shenoy; Aleksandra Petrovic; Kirk R Schultz; Gregory A Yanik; Edmund K Waller; John E Levine; James L Ferrara; Bruce R Blazar; Amelia Langston; John T Horan; Leslie S Kean Journal: J Clin Oncol Date: 2021-01-15 Impact factor: 50.717
Authors: R Mark Simpson; Boris C Bastian; Helen T Michael; Joshua D Webster; Manju L Prasad; Catherine M Conway; Victor M Prieto; Joy M Gary; Michael H Goldschmidt; D Glen Esplin; Rebecca C Smedley; Adriano Piris; Donald J Meuten; Matti Kiupel; Chyi-Chia R Lee; Jerrold M Ward; Jennifer E Dwyer; Barbara J Davis; Miriam R Anver; Alfredo A Molinolo; Shelley B Hoover; Jaime Rodriguez-Canales; Stephen M Hewitt Journal: Pigment Cell Melanoma Res Date: 2013-11-21 Impact factor: 4.693